In all three adolescent patients who received exaluren for eight weeks, kidney biopsies showed measurable increases in collagen IV protein and partial improvement in podocyte structure, the first human evidence that a readthrough therapy can restore a missing structural protein directly in kidney cells. That finding, published in the Journal of Clinical Investigation from Eloxx Pharmaceuticals’ Phase 2a study, now anchors the design logic for the company’s ongoing Phase 2b trial.

The three participants, ages 12 to 18, all had autosomal recessive Alport syndrome driven by a premature stop codon in COL4A4. Daily subcutaneous exaluren at 0.75 mg/kg prompted collagen α3(IV), α4(IV), and α5(IV) to reappear in biopsies, correctly localized. Machine-learning analysis of electron microscopy images found foot process width reductions of 46%, 14%, and 16% across the three patients. Filtration slit density rose by a mean of 50%, reaching more than 80% of healthy control values. Proteinuria changes were inconsistent and the study’s eight-week window was too short to draw conclusions there, but the structural signal at the cellular level was consistent across all participants. Exaluren produced no serious adverse events, no nephrotoxicity, and no ototoxicity, a meaningful safety note given that patients with nonsense mutations in Alport syndrome often reach kidney failure by early adulthood, and many carry pre-existing hearing impairment.

What makes the biopsy data particularly relevant to trial design is that filtration slit density is now the primary efficacy endpoint for the Phase 2b EXACT study (NCT07523581). That randomized, placebo-controlled trial dosed its first patients in September 2026 and targets 24 participants with Alport syndrome caused by nonsense mutations across COL4A3, COL4A4, or COL4A5. The 16-week placebo-controlled portion covers non-U.S. pediatric patients and all adults; topline data are expected mid-2027. Alport syndrome currently has no drugs specifically approved for it, with patients managed through off-label ACE inhibitors, ARBs, and SGLT2 inhibitors aimed at slowing progression rather than correcting the underlying collagen defect.

The number to watch from EXACT is filtration slit density change at 16 weeks in the placebo-controlled cohort. If exaluren moves that endpoint in a controlled setting the way it moved it in three open-label adolescents, the mechanistic case for a genetically targeted kidney therapy becomes substantially harder to dismiss.

Source link: https://www.prnewswire.com/news-releases/eloxx-pharmaceuticals-announces-publication-of-phase-2a-exaluren-data-in-nonsense-mutation-alport-syndrome-in-the-journal-of-clinical-investigation-302944390.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.